

Paroxysmal Nocturnal Hemoglobinuria

**A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition**

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT04654468 YO42311

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study will enrol participants aged 12 years or older with a body weight  $\geq 40$  kilograms (kg) diagnosed with PNH who have not been previously treated with complement inhibitor therapy. Approximately 50 participants will be treated with Crovalimab for at least 24 weeks.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

**NCT04654468 YO42311**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
 $\geq 12$  Years

**Healthy Volunteers**  
No